PETALING JAYA: Malaysia’s arsenal against Covid-19 has got a boost after Sinopharm and Johnson & Johnson vaccines were granted conditional approval for use in the national immunisation programme.
The Health Ministry said the Drug Control Authority (DCA) made the decision at a meeting yesterday.
“This conditional registration approval requires information on the quality, safety and effectiveness of the vaccine product to be monitored and evaluated based on the latest data from time to time.
“It is to ensure that the benefits outweigh the risks for the vaccines,” it said in a statement.
The ministry said it strove to combat the pandemic by ensuring an adequate supply of vaccines that had been evaluated for quality, safety and effectiveness by the National Pharmaceutical Regulatory Division and approved by the DCA.
“The government is committed to ensuring that the Malaysian adult population achieves herd immunity in line with the target of the National Covid-19 Immunisation Programme.
“The meeting has also given conditional approval to Johnson & Johnson’s vaccines that are manufactured by Janssen Pharmaceutica NV in Belgium.
“This follows the Johnson & Johnson vaccines procured from the Covax facility which has been given conditional approval earlier on June 15,” it said.
The immunisation programme now has a total of six vaccines within its portfolio: Pfizer-BioNTech, AstraZeneca, Sinovac, Cansino, Sinopharm and Johnson & Johnson.